Teriparatide, a treatment formula of parathyroid hormone (PTH) , is a powerful 
anabolic agent on bone, improving its mass, geometry and microarchitecture. It 
can decrease the occurrence of fracture in the subjects with increased fracture 
risks. Teriparatide can provide good protection against fracture using as 
monotherapy, and possibly as combination with an antiresorptive agent such as 
zoledronate. Teriparatide should be considered in patients with osteoporosis who 
sustained the reduction of BMD or fracture on established bisphosphonates or 
SERMs. Treatment period of teriparatide is 1.5-2 years and consecutive use of 
antiresorptive agents is greatly recommended to secure long-term protection 
against fracture after teriparatide treatment.